A Phase 3, Prospective, Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multi-center Study of SC411 for Sickle Cell Disease

Trial Profile

A Phase 3, Prospective, Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multi-center Study of SC411 for Sickle Cell Disease

Recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Dec 2016

At a glance

  • Drugs Docosahexaenoic acid (Primary)
  • Indications Sickle cell anaemia
  • Focus Therapeutic Use
  • Acronyms SCOT
  • Sponsors Sancilio & Company
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 19 Dec 2016 According to a Sancilio & Company media release, status changed from not yet recruiting to recruiting.
    • 22 Nov 2016 Planned End Date changed from 1 Dec 2017 to 1 Sep 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top